Treatment with pembrolizumab, a monoclonal antibody targeting programmed death-1, resulted in improved overall survival (OS) compared with chemotherapy for programmed death-ligand 1 (PD-L1) positive NSCLC in the first and second-line settings.1 This evidence concerns the gene CD274 and non-small cell lung carcinoma.